Last reviewed · How we verify
EMB-01
EMB-01 is an investigational monoclonal antibody targeting PD-1.
EMB-01 is an investigational monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | EMB-01 |
|---|---|
| Also known as | FIT-013a, metyrapone, oxazepam |
| Sponsor | Shanghai EpimAb Biotherapeutics Co., Ltd. |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by binding to PD-1 on T cells, preventing its interaction with PD-L1 on tumor cells and thereby enhancing anti-tumor immune response.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pyrexia
Key clinical trials
- Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients (PHASE2)
- EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers (PHASE1, PHASE2)
- EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer (PHASE1, PHASE2)
- A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors (PHASE1, PHASE2)
- Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EMB-01 CI brief — competitive landscape report
- EMB-01 updates RSS · CI watch RSS
- Shanghai EpimAb Biotherapeutics Co., Ltd. portfolio CI